Welcome to our dedicated page for Motus Gi Hldgs news (Ticker: MOTS), a resource for investors and traders seeking the latest updates and insights on Motus Gi Hldgs stock.
Motus GI Holdings, Inc. (NASDAQ: MOTS) delivers innovative solutions for gastrointestinal diagnostics through its FDA-cleared Pure-Vu® system. This dedicated news hub provides investors and healthcare professionals with essential updates on financial performance, regulatory milestones, and clinical adoption progress.
Access timely press releases covering earnings reports, partnership announcements, and technological advancements in colonoscopy preparation. Our curated collection serves as a strategic resource for tracking the company's progress in improving endoscopic visualization and patient outcomes.
Discover updates on U.S. and international commercialization efforts, regulatory submissions, and peer-reviewed clinical data. The content maintains strict adherence to factual reporting standards, ensuring reliable information for investment research and clinical decision-making.
Bookmark this page for streamlined access to Motus GI's latest developments in medical technology. Monitor updates on the Pure-Vu® system's integration into clinical workflows and its growing role in colorectal cancer prevention strategies.
Motus GI Holdings, a medical technology company, reported its Q1 2024 financial results and corporate updates. The U.S. launch of the Pure-Vu® EVS Gastro and Gen 4 Colon system doubled the number of active customers, with 100% adopting the system independently. The company appointed an investment bank to explore strategic alternatives to boost commercialization and stockholder value. Revenues for Q1 2024 increased to $64,000 from $56,000 in Q1 2023, primarily from disposable sleeve reorders. Despite this, the net loss deepened to $7.6 million from $4.4 million year-over-year. Cash and equivalents stood at $4.9 million as of March 31, 2024.